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Abstract
Non small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality world-wide and the majority of cases are
diagnosed at late stages of disease. There is currently no cost-effective screening test for NSCLC, and the development of
such a test is a public health imperative. Recent studies have suggested that chest computed tomography screening of
patients at high risk of lung cancer can increase survival from disease, however, the cost effectiveness of such screening has
not been established. In this Phase I/II biomarker study we examined the feasibility of using serum miRNA as biomarkers of
NSCLC using RT-qPCR to examine the expression of 180 miRNAs in sera from 30 treatment naive NSCLC patients and 20
healthy controls. Receiver operating characteristic curves (ROC) and area under the curve were used to identify differentially
expressed miRNA pairs that could distinguish NSCLC from healthy controls. Selected miRNA candidates were further
validated in sera from an additional 55 NSCLC patients and 75 healthy controls. Examination of miRNA expression levels in
serum from a multi-institutional cohort of 50 subjects (30 NSCLC patients and 20 healthy controls) identified differentially
expressed miRNAs. A combination of two differentially expressed miRNAs miR-15b and miR-27b, was able to discriminate
NSCLC from healthy controls with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)
of 100% in the training set. Upon further testing on additional 130 subjects (55 NSCLC and 75 healthy controls), this miRNA
pair predicted NSCLC with a specificity of 84% (95% CI 0.73–0.91), sensitivity of 100% (95% CI; 0.93–1.0), NPV of 100%, and
PPV of 82%. These data provide evidence that serum miRNAs have the potential to be sensitive, cost-effective biomarkers
for the early detection of NSCLC. Further testing in a Phase III biomarker study in is necessary for validation of these results.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
world-wide, and was responsible for 1.38 million deaths in 2008
[1]. Smoking is the primary risk factor for lung cancer, and it is
estimated that 20.8% of the American adults are active smokers
[2]. Currently there is no validated, cost-effective screening test
that reliably provides a diagnosis of lung cancer. The development
of such a test is a public health imperative since early diagnosis and
treatment of lung cancer is associated with up to a 92% 5-year
survival [3]. Because lung cancer does not usually become
clinically apparent until it reaches an advanced stage, greater
than 75% of lung cancers are diagnosed after the disease is already
locally advanced or metastatic [4]. Due to the substantial survival
advantage to early detection, there have been extensive efforts to
detect lung cancer at an early stage. The Early Lung Cancer
Action Project (ELCAP) [5] and the National Lung Cancer
Screening Trial (NLST) [4] are prospective studies that screened
symptom-free high-risk smokers using low dose computed
tomography (CT) and preliminary results show increased ability
to detect early stage, potentially curable lesions [3]. The NLST
was stopped early in November of 2010 after the preliminary data
revealed a 20.3% decrease in lung cancer deaths in the CT
screening arm of the trial [4,6]. However, the high false positive
rate of 96.4% observed in the low dose CT group is likely to
hinder the adoption of CT scans in population screening [6]. In
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screening for lung cancer remain unanswered [7,8,9,10,11]. Also,
there is some concern that repeated exposure to low dose CT scans
may expose patients to potentially harmful levels of radiation that
could result in more cancers [12]. Although CT scanning can
identify lesions suspicious for lung cancer, tissue diagnosis is the
only way to determine if a lung lesion is cancerous. A meta-
analysis of 7 lung cancer screening studies evaluated low dose
helical CT scanning as a screening test for lung cancer and found
that 14–55% of high-risk patients, with age $40 and $20 pack
year smoking history, who had a suspicious lung lesion on a
screening CT were ultimately found to have benign lung lesions
after undergoing an invasive procedure for tissue diagnosis [13].
This high rate of invasive procedures for benign disease
underscores the necessity for additional screening modalities that
can potentially reduce the number of patients who undergo
invasive procedures unnecessarily.
In addition to the large trials investigating the efficacy of CT
screening for lung cancer, numerous groups are actively
investigating the possibility of blood-based biomarkers for non-
small cell lung cancer (NSCLC) [14]. Circulating biomarkers are
attractive for cancer screening since they are blood-based tests that
are minimally-invasive, relatively low-cost and easily repeatable.
Serum microRNAs (miRNAs) are attractive candidates to be used
as cancer biomarkers. Serum miRNA can be reliably isolated from
serum and have been shown to be highly stable, even under harsh
conditions such as multiple freeze-thaw cycles and changes in pH
[15]. Recent promising studies suggest that plasma miRNAs could
be a useful step in the screening process for lung cancer, and for
deciding which patients to further screen by CT scan [16,17,18].
In an effort to develop non-invasive biomarker assays that can be
used for early detection of lung cancer, we evaluated the
expression of miRNA extracted from serum obtained from pre-
treatment NSCLC patients and cancer-free healthy subjects, to
identify miRNA-based biomarkers that are capable of distinguish-
ing between these groups.
Methods
Sample Collection
Samples used in this study were collected at the University of
Rochester Medical Center by Dr. Stephen Ahrendt as part of a
lung cancer screening study and at The Johns Hopkins Hospital as
part of a head and neck cancer screening protocol. Clinical
information was also collected for each patient at the time of blood
collection. Written informed consent was obtained from all
patients before enrollment in the studies, and the studies were
approved by the University of Rochester Medical Center Research
Subjects Review Board and the Johns Hopkins Hospital
Institutional Review Board, respectively. Blood from NSCLC
patients, and healthy donors was collected into BD VacutainerH
Plus plastic serum tubes and processed into serum. For all cancer
patients, blood was collected at the time of diagnosis but prior to
tumor resection or treatment. The serum was immediately stored
at 280uC until time of use. After the collection process was
completed, all of the records were de-identified to protect patient
confidentiality. Cohorts were compiled retrospectively from these
large collections of serum samples in an effort to compile age and
gender matched cohorts with similar smoking history and with
early stage tumors for cancer patients (Table 1). Patients were
defined as having a history of smoking if they had a history of
consistently smoking for at least one year. A two tailed Fisher’s
exact test was used to determine the associations between All
serum samples are maintained in the tissue bank of the Johns
Hopkins Hospital Division of Head and Neck Cancer Research,
using a web database application provided by The Johns Hopkins
Hospital Department of Oncology’s Research Information
Technology Systems (RITS) (https://www.rits.onc.jhmi.edu/).
Specimens were shipped to Asuragen, Inc., Austin TX for RNA
isolation and evaluation of miRNA and data analysis.
Extraction of Serum RNA
Serum RNA (0.5 ml) was extracted by the Asuragen Pharma-
cogenomics Services Group using the mirVana PARIS Kit
(Ambion, Austin, TX), according to the manufacturer’s instruc-
tions. After the organic extraction, the aqueous phase was loaded
onto the columns provided in the kit. RNA was washed and
extracted as per manufacturer’s instructions. RNA was quantified
using the NanoDrop 1000 (NanoDrop, Wilmington, DE) and
stored at 280C. RNA yields obtained were typically 300–500 ng/
mL of serum.
miRNA Quantification by RT-qPCR
We used TaqMan RT-qPCR assays (Applied Biosystems,
Carlsbad, CA) to examine the expression of 181 miRNAs in
serum RNA of 50 subjects, (30 patients with NSCLC, and 20
cancer-free, healthy subjects). All reagents, primers and probe
were purchased from Applied Biosystems. Reverse transcription
(RT) was performed in 10 uL reactions, each containing 16RT
buffer (Invitrogen, Carlsbad, CA), 250 uM each dNTPs (GE
Healthcare, Piscataway, NJ), 2 uL TaqMan RT primer (Applied
Biosystems, Carlsbad, CA), 4 units of RNAse inhibitor (Promega,
Madison, WI), 10units MMLV-RT (Invitrogen, Carlsbad, CA),
and ,1 ng of RNA per reaction. The reaction mixture was
incubated at 16uC for 30 min, 42uC for 1 hr and 85uC for 5 min.
qPCR reactions were performed using the 384-well ABI Prism
7900 HT Sequence detection system (Applied Biosystems,
Carlsbad, CA). For miRNA screening, one RT and qPCR
reaction per sample was performed, whereas for miRNA
verification assays post screening, two RT reactions followed each
by one qPCR were performed for each of the 130 samples used for
validation. Each qPCR was performed in 15 uL reactions
containing 16 Platinum Taq buffer (Invitrogen, Carlsbad, CA),
5 mM MgCl2 (Invitrogen), 250 uM dNTPs, 2 uL TaqMan
microRNA assay primer/probe mix (Applied Biosystems, Carls-
bad, CA), 16 ROX, (0.5 units Platinum Taq (Invitrogen,
Carlsbad, CA), and 2 uL cDNA from the RT reaction.
Data Analysis
To identify candidate biomarkers for distinguishing NSCLC
from healthy controls, we first calculated the DCt value matrix for
each sample by subtracting the threshold cycle number (Ct) value
for one miRNA from the Ct value of another miRNA in the same
sample. The DCt matrix approach of considering the set of all
differentially expressed miRNA pairs though computationally
burdensome, but has the advantage of obviating the need for
invoking explicit normalizers. For the 181 miRNAs analyzed per
sample, each sample vector yielded 16290 elements (181C2), herein
referred to as miRNA ‘‘diffpairs’’.[19,20] We then computed the
unequal variance t-test p-values and the AUC for the ROC curve
for each of the diffpairs. The cutoff point for each DCt was selected
to maximize the sum of sensitivity and specificity. Candidate
miRNA pairs for verification in another sample set were further
selected based on a sensitivity and specificity of at least 80% each.
These criteria produced a total of 140 candidate miRNA diffpairs
(Figure S1). The cutoff point used for each miRNA diffpair in the
training set was applied in the validation dataset.
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In order to identify differentially expressed miRNA in
NSCLC, we initially screened sera from 16 NSCLC patients
and 20 healthy donors for the expression of 328 miRNA using
RT-qPCR. To avoid false detection, we first eliminated all
miRNAs that were undetected after 40 cycles of qPCR in all
samples, leaving only 181 miRNAs. Consequently, we limited
further screening of sera from 30 NSCLC patients and 20
healthy subjects to only the 181 miRNAs that were expressed at
or below 40 cycles. Patients were matched for age, gender, and
smoking history. A two-tailed Fisher’s exact tests used to analyze
the groups. The only statistically significant association was
between cancer and smoking (p=0.015). Attempts were made to
balance the representation of squamous cell carcinomas and
adenocarcinomas. The majority of the training set samples
(66.7%) were adenocarcinoma, while 33.3% were squamous cell
carcinoma. The demographic characteristics of the 30 NSCLC
patients and 20 healthy patients with no history of cancer are
shown in Figure 1 and Table 1. Although the age range was 20–
75 years in the healthy controls, only one donor was below 35
years old.
Using the differentially expressed miRNA pair-wise data
analysis described above, the training set data on 181 miRNAs
yielded 16290 diff pairs, of which 140 candidate miRNA pairs
distinguished NSCLC from healthy controls with a sensitivity and
specificity of at least 80% each (See Figure S1). Several miRNA
pairs involving miRNAs-106a, miR-15b, miR-27b, miR-142-3p,
miR-26b, miR-182, 126#, let7g, let-7i and miR-30e-5p exhibited
a negative predictive value (NPV) and a positive predictive value
(PPV) of 100% (Table 1), indicating these miRNAs as putative
biomarker candidates for lung cancer diagnosis. The 140
candidate miRNA pairs represented a total of 26 unique miRNAs.
Consequently, RT-qPCR of the 26 miRNAs was performed on
serum RNA from an additional 55 NSCLC patients (60% Stage I,
24% Stage II, 12% Stage III and 4% Stage IV), and from 75
cancer-free, healthy controls. The demographic characteristics of
the 55 NSCLC patients and 75 healthy patients with no history of
cancer are shown in Figure 1 and Table 1. A two-tailed Fisher’s
exact tests used to analyze the groups. The only statistically
significant association was between cancer and smoking
(p=0.005). Differential expression of the candidate biomarker
miRNA pairs from the training set (Figure S1) was examined in
the test set using the same cut-off point as was applied in the
training set. The results yielded 5 candidate biomarkers with a
sensitivity and specificity of at least 75% (Table 2). All the 5
candidate miRNA pairs shown in Table 2 were significantly
differentially expressed between NSCLC and healthy controls, as
indicated by the p-values ,0.001. Differential expression of the
miRNA pair miR-15b/miR-27b is shown in Figure 2 for both the
training set and the test set. The distribution of this miRNA pair
was spread over a broader range (.4 Cts) in the healthy controls,
while the distribution in the NSCLC samples was narrower with a
range of ,2 Cts. The area under curve (AUC) of the receiver
operating characteristic (ROC) plot (Fig. 3) for this miRNA pair
was 0.98 for the test data, with a sensitivity and specificity of 100%
in the training set (Figure S1) and a sensitivity of 100% (95% CI;
0.93–1.0) and specificity of 84% (95% CI 0.73–0.91) in the test set
(Table 2 and Figure 2). The second ranking miRNA pair involved
miR-15a and miR-27b, with a sensitivity of 87% and specificity of
93% in training set, while its sensitivity and specificity in test set
was 94% and 75% respectively (Table 2). Several of the miRNA
pairs in the training set had suboptimal performance in the test set
with either sensitivity and/or specificity less than 75%. The top
candidate miRNA pair (miR-15b and 27b) distinguished NSCLC
from healthy controls with a NPV of 100% and a PPV of 82% in
the test set (Table 2). These findings show the potential of serum-
based miRNA as screening biomarkers for lung cancer.
Table 1. Demographic and histopathologic data for serum samples.
Normal Training Set NSCLC Training Set Normal Test Set NSCLC Test Set
N= 20 30 75 55
Mean Age (years) 54.8 66.5 65.7 68.2
Median Age (years) 54 66 66 68
Age Range (years) 20*–75 56–88 38–85 48–85
Ethnicity
% Caucasian 85 93.3 80.1 94.5
% Africian American 10 3.3 17.3 5.5
% Hispanic 501 . 3 0
% Unknown 03 . 4 1 . 3 0
% Female 45 45 33.3 43.6
%Smoking History 45 80 87 100
% Adenocarcinoma n/a 66.7 n/a 54.5
% Squamous cell carcinoma n/a 33.3 n/a 45.5
% Stage I Tumor n/a 33.3 n/a 60
% Stage II Tumor n/a 30 n/a 24
% Stage III Tumor n/a 33.6 n/a 12
% Stage IV Tumor n/a 0 n/a 4
NSCLC, non-small cell lung cancer; Normal, cancer free, healthy controls.
*Only one healthy control donor was under 35 years.
doi:10.1371/journal.pone.0032307.t001
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In this exploratory Phase I/II biomarker study (as outlined by
the Early Detection Research Network (EDRN) (http://edrn.nci.
nih.gov)) we screened serum from patients with no history of
cancer, and patients with NSCLC in an effort to identify miRNAs
that can be used as biomarkers for the detection of early stage lung
cancer. We identified a miRNA pair miR-15b/miR-27b that was
able to distinguish between serum from NSCLC patients and
cancer-free healthy controls, and with a high degree of sensitivity.
Our results support the findings of recent studies that have shown
that circulating miRNAs profiles may be useful in screening for
NSCLC, [16,17] however, our study included substantially more
patients (180 total) than either of these previous studies. One
drawback of these biomarkers is the low specificity of 84% in the
test set. The relatively high false positive rate for these tests could
be considered unacceptable for screening the general population.
However, in a population of smokers at high risk for lung cancer,
unnecessary screening would be mitigated by the ability of this test,
with its negative predictive value of 100%, to be able to exclude a
large number of patients from going on to more expensive
screening modalities, such as helical chest CT. Although these data
are compelling, further testing in a large, prospective cohort as a
Phase III biomarker study is required to assess the clinical utility of
these miRNA markers as a first line screening test for NSCLC.
The miRNAs markers identified in this study have previously
been implicated in human malignancies. miR-15a and miR-15b
have been shown to be de-regulated in human lung cancer [21].
Both miR-15a and miR-15b have been shown to have a diagnostic
and prognostic value in chronic lymphocytic leukemia [22,23].
miR-27b was found to be down-regulated in lung cancer tissues
compared to non-cancerous lung tissue [24]. In addition, miR-27b
expression levels have been correlated with invasiveness of breast
cancer [25] and with regulation of angiogenesis [26]. A study
involving a total of 86 NSCLC and 57 controls recently revealed a
four miRNA panel in plasma including miR-126 that distin-
guished NSCLC from healthy controls with a sensitivity and
specificity of 73% and 96% respectively [27]. Using whole blood,
Keller and coworkers [28] showed that miR-126 and miR-98 were
among the top miRNAs that could distinguish NSCLC from
healthy controls. miR-126 is highly expressed in lung tissue and is
involved in the regulation of vascular cell adhesion molecule 1
(VCAM-I) [29]. Aberrant expression of miR-126 has been
implicated in the pathogenesis of NSCLC [30,31]. In this study,
several pairs involving miR-126 were among the several
candidates identified in the training set (Figure S1), however upon
further testing in additional 130 samples, all the miRNA-126
candidate pairs exhibited sensitivity greater than 75% and the
specificity was less than 75%. Other recent studies by Foss and
coworkers [17] showed serum miR-1254 and miR-574-5p were
differentially expressed between NSCLC (n=33) and healthy
controls (n=42). It is important to note that several factors affect
the outcome of miRNA studies in biofluids, including variations in
sample type e.g. whole blood, plasma or serum, sample numbers,
study design, sample collection, RNA isolation, patient character-
istics, number of miRNA examined and technologies used in
miRNA profiling e.g. solexa sequencing, RT-qPCR or microarray
technologies. In addition, standardization of isolation methods,
normalization and data analysis methods is needed in order to
demonstrate a clear clinical utility of these putative markers.
Although these data are promising, the test set included a
relatively small number of samples. Ultimately, these miRNA
biomarkers require further validation on larger prospective cohorts
such as a Phase III biomarker study in order to validate these
results. Incorporating blood-based miRNA markers in spiral CT
studies may aid in exploring the utility of miRNAs in screening of
lung cancer. Although this is an exploratory phase I/II trial, the
patients were selected primarily from surgical clinics, and are
weighted towards early stage disease (60% Stage I, 24% Stage II,
12% Stage III and 4% Stage IV). This skew towards early stage
disease supports the investigation of these markers in a phase III or
IV trial aimed at defining the performance of these markers in a
prospective manner in early stage detection.
Figure 1. Retrospective study design used to identify miRNA that could distinguish healthy controls (normal) from lung cancer
patients.
doi:10.1371/journal.pone.0032307.g001
Table 2. Differential miRNA expression in sera from NSCLC
patients (cancer) and healthy controls (normal) in test set.
miRpair PPV NPV SENS SPEC p-value
Diff(15b,27b) 82% 100% 100% 84% 3.70E-25
Diff(15a,27b) 73% 95% 94% 75% 4.01E-16
Diff(142-3p,27b) 73% 89% 87% 76% 2.36E-13
Diff(15b,301) 89% 83% 75% 93% 2.17E-16
Diff(27b,301) 69% 80% 75% 76% 1.52E-08
Diff, differential expression between the two miRNAs, calculated as the
difference between Ct values of the two indicated miRNAs. PPV, positive
predictive value; NPV, negative predictive value; SENS, sensitivity; and SPEC,
specificity. The cutoff value used in training set was applied in the test set.
doi:10.1371/journal.pone.0032307.t002
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doi:10.1371/journal.pone.0032307.g003
Figure 2. Differential expression of miRNA diffpair miR-15b/miR27-b in sera from healthy donors (normal) and from lung cancer
patients (cancer). Differential expression values were calculated as a difference of the Ct values for the two miRNAs. The threshold indicated by the
horizontal line was selected to maximize the sum of sensitivity and specificity as described in data analysis. The sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) obtained using the differential expression of the 2 miRNA displayed as tables for the
training set (on the right) and the test set (on the left).
doi:10.1371/journal.pone.0032307.g002
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CT scans for reduction in mortality from lung cancer from the
NLST trial places a premium on identification of high risk
individuals who could benefit from screening. Adjunctive serum
based testing may be performed in a highly cost effective manner
compared to imaging, and may be helpful to identify high risk
populations that may benefit from chest CT, or to be used in
combination with imaging to identify early lung cancers.
There is great need for improved screening for lung cancer
given the large number of people affected each year and the high
mortality rate of the disease when diagnosed in its later stages.
There are currently numerous clinical trials being conducted to
test the efficacy of novel therapies for NSCLC, however, the
majority of these are Phase II trials and recently a number of
Phase III trials have failed to meet their primary end points [32]
To date, improved screening to provide early detection is the most
promising avenue to reduce mortality from NSCLC. Our study
further strengthens the argument that serum miRNA have the
potential to be used as a cost effective, non-invasive diagnostic test
for NSCLC, and could potentially be used as a first line screen to
help risk stratify patients for further, more expensive or invasive
screening regimens.
Supporting Information
Figure S1 Differential miRNA expression in sera from
NSCLC patients (cancer) and healthy controls (normal)
in training set. Diff, differential expression between the two
miRNAs, calculated as the difference between Ct values of the two
indicated miRNAs. PPV, positive predictive value; NPV, negative
predictive value; SENS, sensitivity; and SPEC, specificity. The
cutoff value used to achieve the indicated specificity and sensitivity
is indicated for each miRNA diff pair.
(XLS)
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